Checked 2026-11-10. Independent clinical review has not been completed. WADAFUK is independent of WADA and does not provide medical advice or an individual anti-doping determination.
Conditional restriction
WADA 2026: intravenous administration as an S5 plasma expander is prohibited at all times and specified. The route qualification is retained in the future 2027 List. [1] [2]
2026 and 2027 List, S5, printed p.12; introductory definitions p.3 · 2026 rules apply from 1 January 2026. Any 2027 material below concerns future rules from 1 January 2027; it is not current clearance.
Medical and pharmacological context
The reviewed US dextran 40 injection label includes adjunctive treatment of shock or impending shock after hemorrhage, burns, surgery or trauma. This is a plasma-volume-expanding medicinal preparation. [3]
- The cited country-specific product information does not establish worldwide authorization or current supply.
Health concerns
Severe, sometimes fatal anaphylactoid reactions are described, together with fluid or solute overload. The label does not establish equivalent risks for every dextran-containing product. [3]
- Selected warnings, not a complete contraindication or interaction list. Patient-label evidence does not establish athlete safety.
Additional anti-doping conditions
When a prohibited diuretic or masking agent is detected with formoterol, salbutamol, cathine, ephedrine, methylephedrine or pseudoephedrine, S5 has an additional TUE requirement even below the usual threshold. The note expressly excludes qualifying carbonic-anhydrase-inhibitor eye administration and local dental felypressin. It is not a dosing or test-clearance rule. [1] [2]
- A prescription or medical indication is not itself a TUE approval.
Route and procedure matter
The S5 entry is intravenous-specific. Separately, M2 governs IV procedures, including volume and medical-setting exceptions. A permitted procedure does not automatically authorize a prohibited substance. Ordinary oral exposure is not intravenous plasma expansion. [1] [2]
- Other ingredients and other applicable rules still require checking.
Iron dextran is a distinct context
WADA explains that IV iron dextran is not treated as a prohibited plasma expander because the dextran is bound in the iron complex. The separate M2 procedure rules still need checking. [4]
What remains uncertain
- Educational synthesis only; not individualized medical advice, a TUE decision or a sanction prediction.
Check the sources.
These are concise editorial paraphrases of selected sources, not a systematic review or a reproduction of source tables. Access depth is shown for each reference; an abstract-only check cannot resolve details found only in a full paper.
- WADA 2026 Prohibited List ↗Accessed 2026-11-10 · relevant full-text sections independently opened and inspected
Introduction p.3 · S5 p.12 · M2.2 p.13
- WADA 2027 Prohibited List, 4 November revision ↗Accessed 2026-11-10 · relevant full-text sections independently opened and inspected · FUTURE 2027 SOURCE
Introduction p.3 · S5 p.12 · M2.2 p.13
- Dextran 40 injection prescribing information, DailyMed ↗Accessed 2026-11-10 · relevant full-text sections independently opened and inspected
Indications; clinical pharmacology or SmPC sections 4.1 and 5.1 · Warnings, precautions and adverse reactions
- WADA Prohibited List and FAQs ↗Accessed 2026-11-10 · relevant full-text sections independently opened and inspected
FAQ: eye drops containing beta-blockers · FAQ: intravenous iron dextran · WADA mannitol FAQ; Bronchitol indication and bronchospasm warning
Check the current official WADA List and the relevant anti-doping authority for your sport, product, route and circumstances. Do not stop or change necessary treatment based on this page. Ask a qualified clinician about health decisions. Missing evidence does not establish safety.